E3810 + E3810 + Teprenone
Phase 2/3Completed 1 views this week 0 watching💤 Quiet
Interest: 38/100
38
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Gastric or Duodenal Ulcers Caused by Low-dose Aspirin
Conditions
Gastric or Duodenal Ulcers Caused by Low-dose Aspirin
Trial Timeline
Jul 1, 2011 → Jun 1, 2013
NCT ID
NCT01397448About E3810 + E3810 + Teprenone
E3810 + E3810 + Teprenone is a phase 2/3 stage product being developed by Eisai for Gastric or Duodenal Ulcers Caused by Low-dose Aspirin. The current trial status is completed. This product is registered under clinical trial identifier NCT01397448. Target conditions include Gastric or Duodenal Ulcers Caused by Low-dose Aspirin.
What happened to similar drugs?
5 of 20 similar drugs in Gastric or Duodenal Ulcers Caused by Low-dose Aspirin were approved
Approved (5) Terminated (3) Active (13)
Hype Score Breakdown
Clinical
15
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01397448 | Phase 2/3 | Completed |
Competing Products
20 competing products in Gastric or Duodenal Ulcers Caused by Low-dose Aspirin